RxDoctor Payments DataLook up a doctor →

Lawrence Goldstick, MD

Neurology · Dayton, OHNPI 1508969445

Payments from drug & device makers

$6,851,363in general payments, 2019–2025

Across 1,941 payments — averaging $3529.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2M
  • Eli Lilly$1.2M
  • Biogen$1.1M
  • Novartis$931K
  • Sanofi$628K
  • TG Therapeutics, Inc.$377K
  • plus $542K from 50 others
$43,508in research payments, 2019–2025

Across 43 payments — averaging $1011.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$32K
  • Eli Lilly$10K
  • Sanofi US Services Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.150$2,048,127
Eli Lilly41$1,215,809
Biogen244$1,109,139
Novartis106$931,219
Sanofi152$628,396
TG Therapeutics, Inc.67$377,010
EMD Serono, Inc.241$197,405
Alkermes, Inc.44$133,259
Bristol Myers Squibb67$55,882
Mallinckrodt Enterprises LLC18$41,539
Jazz Pharmaceuticals Inc.5$28,666
Genentech USA, Inc.106$25,776
E.r. Squibb & Sons, L.L.C.12$24,625
Mallinckrodt Hospital Products Inc.18$8,384
F. Hoffmann-la Roche AG4$7,531
Lilly USA, LLC69$4,652
Hoffmann-la Roche Limited3$2,206
Amgen(2 entities)33$2,051
AbbVie(2 entities)58$1,191
AstraZeneca32$1,030
Supernus Pharmaceuticals, Inc.101$957
SK Life Science, Inc.35$779
Eisai Inc.40$715
Teva Pharmaceuticals USA, Inc.48$702
Acorda Therapeutics, Inc41$406
UCB, Inc.19$399
Pfizer25$388
Sunovion Pharmaceuticals Inc.29$356
Johnson & Johnson14$343
Neurocrine Biosciences, Inc.15$281
Avanir Pharmaceuticals, Inc.11$251
Acadia Pharmaceuticals Inc13$234
Greenwich Biosciences, Inc.10$208
Corium, LLC10$193
Neurelis, Inc.8$139
Biohaven Pharmaceutical Holding Company Ltd.7$138
Biohaven Pharmaceuticals, Inc.6$125
Axsome Therapeutics, Inc.3$122
MDD US Operations, LLC6$109
Lundbeck LLC4$108
Amneal Pharmaceuticals LLC3$63
Argenx US, Inc.2$59
Catalyst Pharmaceuticals, Inc.2$55
Avion Pharmaceuticals3$48
Cycle Pharmaceuticals Inc2$45
Aquestive Therapeutics, Inc.2$41
Otsuka America Pharmaceutical, Inc.2$37
ANI Pharmaceuticals, Inc.1$27
Banner Life Sciences, LLC2$26
Livanova USA, Inc.1$25
Vanda Pharmaceuticals Inc.1$19
Aprecia Pharmaceuticals, LLC1$15
Adamas Pharmaceuticals, Inc.1$15
Amylyx Pharmaceuticals, Inc.1$14
Kyowa Kirin, Inc.1$13
Scilex Pharmaceuticals Inc.1$13

How this compares

$6,851,363 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024
$419,863
Medicare patients
198
Services billed
8,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dayton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →